{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T14:26:43Z","timestamp":1776695203478,"version":"3.51.2"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.rdc.2022.02.004","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T18:32:29Z","timestamp":1649356349000},"page":"445-454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Statin-Associated Myalgias and Muscle Injury\u2014Recognizing and Managing Both While Still Lowering the Low-Density Lipoprotein"],"prefix":"10.1016","volume":"48","author":[{"given":"Andrew L.","family":"Mammen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.rdc.2022.02.004_bib1","doi-asserted-by":"crossref","first-page":"e0190688","DOI":"10.1371\/journal.pone.0190688","article-title":"Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England","volume":"13","author":"Ueda","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.rdc.2022.02.004_bib2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"issue":"3 Suppl","key":"10.1016\/j.rdc.2022.02.004_bib3","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"issue":"7","key":"10.1016\/j.rdc.2022.02.004_bib4","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-Associated Autoimmune Myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.rdc.2022.02.004_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"10.1016\/j.rdc.2022.02.004_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","article-title":"A\u00a0systematic review of statin-induced muscle problems in clinical trials","volume":"168","author":"Ganga","year":"2014","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.rdc.2022.02.004_bib7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.rdc.2022.02.004_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","article-title":"A\u00a0randomized trial of coenzyme Q10 in patients with confirmed statin myopathy","volume":"238","author":"Taylor","year":"2015","journal-title":"Atherosclerosis"},{"issue":"15","key":"10.1016\/j.rdc.2022.02.004_bib9","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.rdc.2022.02.004_bib10","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.jacc.2017.07.767","article-title":"Application of the Statin-Associated Muscle Symptoms-Clinical Index to a Randomized Trial on Statin Myopathy","volume":"70","author":"Taylor","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.rdc.2022.02.004_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.atherosclerosis.2013.07.001","article-title":"Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance","volume":"230","author":"Ballard","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.rdc.2022.02.004_bib12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijcard.2016.02.028","article-title":"Increased creatine kinase with statin treatment may identify statin-associated muscle symptoms","volume":"209","author":"Taylor","year":"2016","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.rdc.2022.02.004_bib13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10557-017-6723-4","article-title":"The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability","volume":"31","author":"Rosenson","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"10.1016\/j.rdc.2022.02.004_bib14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.0197-3118.2005.04404.x","article-title":"Decreasing LDL cholesterol and medication cost with every-other-day statin therapy","volume":"8","author":"Juszczyk","year":"2005","journal-title":"Prev Cardiol"},{"issue":"14","key":"10.1016\/j.rdc.2022.02.004_bib15","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"Lloyd-Jones","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.rdc.2022.02.004_bib16","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"issue":"23","key":"10.1016\/j.rdc.2022.02.004_bib17","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"33","key":"10.1016\/j.rdc.2022.02.004_bib18","doi-asserted-by":"crossref","first-page":"e4344","DOI":"10.1097\/MD.0000000000004344","article-title":"Creatine kinase in the U.S. population: Impact of demographics, comorbidities, and body composition on the normal range","volume":"95","author":"George","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.rdc.2022.02.004_bib19","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy--a genomewide study","volume":"359","author":"Group","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2022.02.004_bib20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1016\/j.rdc.2022.02.004_bib21","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jacc.2016.04.037","article-title":"Statin-Induced Anti-HMGCR-Associated Myopathy","volume":"68","author":"Basharat","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.rdc.2022.02.004_bib22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/acr.20662","article-title":"Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.rdc.2022.02.004_bib23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/mus.25127","article-title":"Absence of anti-HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy","volume":"54","author":"Floyd","year":"2016","journal-title":"Muscle Nerve"},{"issue":"17","key":"10.1016\/j.rdc.2022.02.004_bib24","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous immune globulin for statin-triggered autoimmune myopathy","volume":"373","author":"Mammen","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.rdc.2022.02.004_bib25","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/art.40919","article-title":"Use of Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) inhibitors in statin-associated immune mediated necrotizing myopathy: a case-series","volume":"71","author":"Tiniakou","year":"2019","journal-title":"Arthritis Rheumatol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X22000047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X22000047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:30:49Z","timestamp":1760182249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X22000047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0889857X22000047"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2022.02.004","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin-Associated Myalgias and Muscle Injury\u2014Recognizing and Managing Both While Still Lowering the Low-Density Lipoprotein","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2022.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}